GTBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GT Biopharma Inc (GTBP) is not a strong buy for a beginner long-term investor at this time. The company is in the early stages of clinical trials with no revenue growth, high net losses, and limited cash reserves. While analysts maintain a Buy rating, the reduced price target and lack of near-term catalysts make this a speculative investment. The technical indicators also show no clear bullish trend, and there are no proprietary trading signals or significant political/influential trading activity to support a buy decision.
The MACD is slightly positive and expanding, indicating weak bullish momentum. However, the RSI is neutral at 49.537, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near a pivot level of 0.458, with resistance at 0.485 and support at 0.431. Overall, the technical indicators do not suggest a strong buy signal.
The company is advancing its pipeline with Phase 1 trials for innovative therapies targeting hematologic malignancies and solid tumors. Analysts maintain a Buy rating despite lowering the price target.
The company reported a significant net loss of $28.4 million for FY2025, with no revenue growth. Cash reserves are limited to $9 million, raising concerns about funding sustainability. Analysts have reduced the price target from $8 to $3, citing increased dilution and the need for ongoing funding. No near-term catalysts are expected, with initial trial data not due until 3Q26.
For Q4 2025, the company reported no revenue growth, a net income loss of $28.9 million (up 665.48% YoY), and an EPS of -2.23 (up 33.53% YoY). Operating losses improved slightly, but the company remains unprofitable with limited cash reserves.
Roth Capital maintains a Buy rating but has lowered the price target from $8 to $3 due to increased dilution and funding concerns. The company is focused on advancing its pipeline, but the timeline for data and trials extends into 2026, offering no immediate upside.
